{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:26:19Z","timestamp":1793755579850,"version":"4.6.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-024-08634-4","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T14:50:09Z","timestamp":1732027809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A phase 1 randomized controlled trial of a peptide-based group A streptococcal vaccine in healthy volunteers"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4004-4940","authenticated-orcid":false,"given":"Vanessa","family":"Meier-Stephenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Hawkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainslie","family":"Calcutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Good","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Houghton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloise","family":"Keeffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailin","family":"Lepletier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conar","family":"O\u2019Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ijeoma","family":"Ogbuehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Ozberk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avi","family":"Seth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Tse-Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Tyrrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Lorne","family":"Tyrrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Tyrrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryna","family":"Yaskina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"8634_CR1","unstructured":"WHO. World Health Organization (15 December 2022). Disease outbreak news; increased incidence of scarlet fever and invasive group A Streptococcus infection - multi-country. 2022.\u00a0https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2022-DON429."},{"issue":"13","key":"8634_CR2","doi-asserted-by":"publisher","first-page":"e025284","DOI":"10.1161\/JAHA.122.025284","volume":"11","author":"SH Ghamari","year":"2022","unstructured":"Ghamari SH, Abbasi-Kangevari M, Saeedi Moghaddam S, Aminorroaya A, Rezaei N, Shobeiri P, et al. Rheumatic heart disease is a neglected disease relative to its burden worldwide: findings from global burden of disease 2019. J Am Heart Assoc. 2022;11(13):e025284.","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"8634_CR3","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1473-3099(09)70178-1","volume":"9","author":"AC Steer","year":"2009","unstructured":"Steer AC, Law I, Matatolu L, Beall BW, Carapetis JR. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis. 2009;9(10):611\u20136.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"8634_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.7774\/cevr.2016.5.2.101","volume":"5","author":"JL Excler","year":"2016","unstructured":"Excler JL, Kim JH. Accelerating the development of a group A Streptococcus vaccine: an urgent public health need. Clin Exp Vaccine Res. 2016;5(2):101\u20137.","journal-title":"Clin Exp Vaccine Res"},{"issue":"7","key":"8634_CR5","first-page":"833","volume":"12","author":"JB Dale","year":"2005","unstructured":"Dale JB, Penfound T, Chiang EY, Long V, Shulman ST, Beall B. Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes. Clin Diagn Lab Immunol. 2005;12(7):833\u20136.","journal-title":"Clin Diagn Lab Immunol"},{"issue":"46","key":"8634_CR6","doi-asserted-by":"publisher","first-page":"8175","DOI":"10.1016\/j.vaccine.2011.09.005","volume":"29","author":"JB Dale","year":"2011","unstructured":"Dale JB, Penfound TA, Chiang EY, Walton WJ. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine. 2011;29(46):8175\u20138.","journal-title":"Vaccine"},{"issue":"6","key":"8634_CR7","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.vaccine.2019.12.005","volume":"38","author":"\u00c9 Pastural","year":"2020","unstructured":"Pastural \u00c9, McNeil SA, MacKinnon-Cameron D, Ye L, Langley JM, Stewart R, et al. Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: a randomized, controlled phase I study. Vaccine. 2020;38(6):1384\u201392.","journal-title":"Vaccine"},{"issue":"1","key":"8634_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41541-023-00609-x","volume":"8","author":"DR Walkinshaw","year":"2023","unstructured":"Walkinshaw DR, Wright MEE, Mullin AE, Excler JL, Kim JH, Steer AC. The Streptococcus pyogenes vaccine landscape. NPJ Vaccines. 2023;8(1):16.","journal-title":"NPJ Vaccines"},{"issue":"8923","key":"8634_CR9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S0140-6736(94)92083-4","volume":"344","author":"S Pruksakorn","year":"1994","unstructured":"Pruksakorn S, Currie B, Brandt E, Martin D, Galbraith A, Phornphutkul C, et al. Towards a vaccine for rheumatic fever: identification of a conserved target epitope on M protein of group A streptococci. Lancet. 1994;344(8923):639\u201342.","journal-title":"Lancet"},{"issue":"3","key":"8634_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1046\/j.1365-2567.1996.d01-754.x","volume":"89","author":"ER Brandt","year":"1996","unstructured":"Brandt ER, Hayman WA, Currie B, Carapetis J, Wood Y, Jackson DC, et al. Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci. Immunology. 1996;89(3):331\u20137.","journal-title":"Immunology"},{"issue":"16","key":"8634_CR11","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/S0264-410X(97)00178-3","volume":"15","author":"ER Brandt","year":"1997","unstructured":"Brandt ER, Hayman WA, Currie B, Pruksakorn S, Good MF. Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci. Vaccine. 1997;15(16):1805\u201312.","journal-title":"Vaccine"},{"issue":"11","key":"8634_CR12","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/intimm\/9.11.1723","volume":"9","author":"WA Hayman","year":"1997","unstructured":"Hayman WA, Brandt ER, Relf WA, Cooper J, Saul A, Good MF. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int Immunol. 1997;9(11):1723\u201333.","journal-title":"Int Immunol"},{"issue":"8","key":"8634_CR13","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.4049\/jimmunol.1700836","volume":"199","author":"T Nordstrom","year":"2017","unstructured":"Nordstrom T, Pandey M, Calcutt A, Powell J, Phillips ZN, Yeung G, et al. Enhancing vaccine efficacy by engineering a complex synthetic peptide to become a super immunogen. J Immunol. 2017;199(8):2794\u2013802 (Baltimore, Md\u202f: 1950).","journal-title":"J Immunol"},{"issue":"36","key":"8634_CR14","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.1016\/j.vaccine.2009.06.042","volume":"27","author":"CE Turner","year":"2009","unstructured":"Turner CE, Kurupati P, Wiles S, Edwards RJ, Sriskandan S. Impact of immunization against SpyCEP during invasive disease with two streptococcal species: Streptococcus pyogenes and Streptococcus equi. Vaccine. 2009;27(36):4923\u20139.","journal-title":"Vaccine"},{"issue":"2","key":"8634_CR15","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.chom.2008.07.002","volume":"4","author":"AS Zinkernagel","year":"2008","unstructured":"Zinkernagel AS, Timmer AM, Pence MA, Locke JB, Buchanan JT, Turner CE, et al. The IL-8 protease SpyCEP\/ScpC of group A Streptococcus promotes resistance to neutrophil killing. Cell Host Microbe. 2008;4(2):170\u20138.","journal-title":"Cell Host Microbe"},{"issue":"12","key":"8634_CR16","doi-asserted-by":"publisher","first-page":"5915","DOI":"10.4049\/jimmunol.1500157","volume":"194","author":"M Pandey","year":"2015","unstructured":"Pandey M, Langshaw E, Hartas J, Lam A, Batzloff MR, Good MF. A synthetic M protein peptide synergizes with a CXC chemokine protease to induce vaccine-mediated protection against virulent streptococcal pyoderma and bacteremia. J Immunology. 2015;194(12):5915\u201325 (Baltimore, Md\u202f: 1950).","journal-title":"J Immunology"},{"issue":"8","key":"8634_CR17","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.4049\/jimmunol.1501994","volume":"196","author":"M Pandey","year":"2016","unstructured":"Pandey M, Mortensen R, Calcutt A, Powell J, Batzloff MR, Dietrich J, et al. Combinatorial synthetic peptide vaccine strategy protects against hypervirulent CovR\/S mutant streptococci. J Immunol. 2016;196(8):3364\u201374 (Baltimore, Md\u202f: 1950).","journal-title":"J Immunol"},{"key":"8634_CR18","unstructured":"NIH. Division of Microbiology and Infectious Diseases (DMID) adult toxicity table: National Institute for Allergy and Infectious Diseases. 2007. Available from: https:\/\/www.niaid.nih.gov\/LabsAndResources\/resources\/DMIDClinRsrch\/Documents\/dmidadulttox.pdf."},{"key":"8634_CR19","doi-asserted-by":"publisher","unstructured":"Ozberk V, Reynolds S, Huo Y, Calcutt A, Eskandari S, Dooley J, et al. Prime-pull immunization with a bivalent M-protein and spy-CEP peptide vaccine adjuvanted with CAF(R)01 liposomes induces both mucosal and peripheral protection from covR\/S mutant Streptococcus pyogenes. mBio. 2021;12(1):e03537\u201320.\u00a0https:\/\/doi.org\/10.1128\/mBio.03537-20.","DOI":"10.1128\/mBio.03537-20"},{"issue":"7","key":"8634_CR20","doi-asserted-by":"publisher","first-page":"e0198658","DOI":"10.1371\/journal.pone.0198658","volume":"13","author":"S Sekuloski","year":"2018","unstructured":"Sekuloski S, Batzloff MR, Griffin P, Parsonage W, Elliott S, Hartas J, et al. Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial. PLoS ONE. 2018;13(7):e0198658.","journal-title":"PLoS ONE"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08634-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-024-08634-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08634-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T15:02:19Z","timestamp":1732028539000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-024-08634-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["8634"],"URL":"https:\/\/doi.org\/10.1186\/s13063-024-08634-4","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]},"assertion":[{"value":"27 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The University of Alberta Human Research Ethics Board (HREB) has assessed and approved this protocol as well as the consent form and all trial related documents\u2014REB Pro00089919, ver 05Oct2023. Written, informed consent to participate will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable. No identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. The participant information materials and informed consent form are available from the corresponding author upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"MG and MP are co-inventors on the patents related to the vaccine candidates in trial.The remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"781"}}